SAB Biotherapeutics (SABS) Other Working Capital Changes (2022 - 2026)

SAB Biotherapeutics (SABS) has 5 years of Other Working Capital Changes data on file, last reported at $297263.0 in Q1 2026.

• Quarterly Other Working Capital Changes rose 2.13% year-over-year to $297263.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 793.83% YoY) and the FY2025 annual result came in at $5.3 million, up 795.11% from the prior year.
• Other Working Capital Changes retreated to $297263.0 in Q1 2026, from $6.9 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $6.9 million in Q4 2025 to a low of -$2.1 million in Q3 2025.
• A 5-year average of $528242.4 and a median of $144020.0 in 2024 frame the typical range for Other Working Capital Changes.
• The widest YoY moves for Other Working Capital Changes: up 612.67% in 2025, down 8348.53% in 2025.
• Tracing SABS's Other Working Capital Changes over 5 years: stood at -$100000.0 in 2022, then soared by 2310.66% to $2.2 million in 2023, then slumped by 56.44% to $963014.0 in 2024, then jumped by 612.67% to $6.9 million in 2025, then plunged by 95.67% to $297263.0 in 2026.
• The last three Other Working Capital Changes figures came in at $297263.0 (Q1 2026), $6.9 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.